Fracture Recovery for Returning to Duty (Teriparatide STRONG)

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

183

Participants

Timeline

Start Date

December 8, 2022

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2026

Conditions
Stress Fracture of Tibia or Fibula
Interventions
DRUG

Teriparatide

Teriparatide, an injectable synthetic parathyroid hormone, will be tested to evaluate its efficacy for decreasing the convalescence after a diaphyseal tibial stress fracture, a specific bone stress injury.

DRUG

Placebos

Placebo will be a sugar solution of the manufacturer's design.

Trial Locations (1)

29207

Fort Jackson, Columbia

All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

Eisenhower Army Medical Center

FED

collaborator

Moncrief Army Health Clinic

UNKNOWN

lead

University of South Carolina

OTHER